Realfiction (REALFI) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
27 Nov, 2025Executive summary
Q3-2025 revenue dropped 94% year-over-year to TSEK 606, mainly due to the absence of DPT project sales and lower legacy display sales.
Gross profit margin fell to 51.8% from 82.1% in Q3-2024, reflecting the lack of high-margin DPT sales.
Operating loss deepened to TSEK -6,359 in Q3-2025 from a profit of TSEK 699 in Q3-2024.
Rights issue in August 2025 raised approximately SEK 30 million, strengthening the capital base.
Commercial discussions for DPT platform advanced, with new demonstrator showcased to potential partners.
Financial highlights
Q3-2025 revenue: TSEK 606 (Q3-2024: TSEK 9,835); Q1-Q3 2025 revenue: TSEK 2,612 (Q1-Q3 2024: TSEK 14,046).
Q3-2025 gross profit: TSEK 314 (Q3-2024: TSEK 8,074); gross margin: 51.8% (Q3-2024: 82.1%).
Q3-2025 result after financial items: TSEK -7,445 (Q3-2024: TSEK -340); Q1-Q3 2025: TSEK -23,516 (Q1-Q3 2024: TSEK -16,971).
Q3-2025 EPS: SEK -0.35 (Q3-2024: SEK -0.02); Q1-Q3 2025 EPS: SEK -1.15 (Q1-Q3 2024: SEK -0.86).
Cash flow from operating activities Q3-2025: TSEK -7,900 (Q3-2024: TSEK -4,082).
Outlook and guidance
Focus remains on commercializing DPT technology, with expectations to secure agreements in 2025 and 2026.
Revenue from legacy displays expected to continue declining as focus shifts to DPT.
Q4-2025 has started with improved revenue, tracking above Q3 and highest since Q4-2024.
Funding from rights issue and TO2 warrants expected to support commercialization efforts.
Latest events from Realfiction
- SEK 50 million rights issue supports commercialization of advanced glasses-free 3D display tech.REALFI
Status Update23 Nov 2025 - DPT commercialization advances with improved margins and new funding, despite lower revenue.REALFI
Q2 202528 Jul 2025 - Q3-2024 saw record DPT-driven revenue growth and strong gross margins, with liquidity secured.REALFI
Q3 202413 Jun 2025 - Q2-2024 saw strong revenue growth and DPT licensing talks nearing a breakthrough.REALFI
Q2 202413 Jun 2025 - DPT commercialization accelerates with new funding and industry milestones despite lower revenue.REALFI
Q1 20256 Jun 2025 - Revenue surged and DPT commercialization advanced with a pivotal license agreement.REALFI
Q4 20245 Jun 2025